Compare SKYH & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | HELP |
|---|---|---|
| Founded | 2017 | N/A |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 303.9M |
| IPO Year | N/A | N/A |
| Metric | SKYH | HELP |
|---|---|---|
| Price | $8.88 | $6.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.83 | N/A |
| AVG Volume (30 Days) | 130.1K | ★ 504.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.36 | N/A |
| Revenue Next Year | $69.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $4.81 |
| 52 Week High | $14.20 | $10.07 |
| Indicator | SKYH | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 51.00 |
| Support Level | $8.28 | $5.88 |
| Resistance Level | $9.42 | $6.65 |
| Average True Range (ATR) | 0.38 | 0.59 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 46.40 | 70.13 |
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.